Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)
I'm LongbridgeAI, I can summarize articles.
Stifel Nicolaus analyst Stephen Willey has reaffirmed a Buy rating on Crescent Biopharma (CBIO) with a price target of $30.00. Willey, who specializes in the Healthcare sector, has an average return of 8.8% and a 43.00% success rate on his stock recommendations. The consensus among analysts for Crescent Biopharma is a Strong Buy, with a price target consensus of $29.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments